Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 2—February 2007
Dispatch

Ertapenem Resistance of Escherichia coli

Marie-Frédérique Lartigue*, Laurent Poirel*, Claire Poyart†, Hélène Réglier-Poupet†, and Patrice Nordmann*Comments to Author 
Author affiliations: *Université Paris XI, Kremlin-Bicêtre, France; †Université Paris V, Paris, France;

Main Article

Figure

Outer membrane protein (OMP) profiles of Escherichia coli strains. OMP content was determined by using sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Lane 1 corresponds to E. coli CO clinical isolate; lane 2, E. coli JF 568 strain expressing OmpC; lane 3, E. coli JF 701 strain lacking OmpC (9). The molecular mass marker (M) and corresponding sizes (in kilodaltons) are indicated on the left. Horizontal arrows on the right indicate positions of the OMPs OmpF, OmpC, and OmpA.

Figure. Outer membrane protein (OMP) profiles of Escherichia coli strains. OMP content was determined by using sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Lane 1 corresponds to E. coli CO clinical isolate; lane 2, E. coli JF 568 strain expressing OmpC; lane 3, E. coli JF 701 strain lacking OmpC (9). The molecular mass marker (M) and corresponding sizes (in kilodaltons) are indicated on the left. Horizontal arrows on the right indicate positions of the OMPs OmpF, OmpC, and OmpA.

Main Article

References
  1. Jacoby G, Han P, Tran J. Comparative in vitro activities of carbapenem L-749, 345 and other antimicrobials against multiresistant gram-negative clinical pathogens.Antimicrob Agents Chemother. 1997;41:18301.PubMedGoogle Scholar
  2. Nordmann P, Poirel L. Emerging carbapenemases in gram-negative aerobes.Clin Microbiol Infect. 2002;8:32131. DOIPubMedGoogle Scholar
  3. Jacoby GA, Mills DM, Chow N. Role of β-lactamases and porins in resistance to ertapenem and other β-lactams in Klebsiella pneumoniae.Antimicrob Agents Chemother. 2004;48:32036. DOIPubMedGoogle Scholar
  4. Elliott E, Brink AJ, Van Greune J, Els Z, Woodford N, Turton J, In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase.Clin Infect Dis. 2006;42:958. DOIPubMedGoogle Scholar
  5. Poirel L, Heritier C, Spicq C, Nordmann P. In vivo acquisition of high-level resistance to imipenem in Escherichia coli.J Clin Microbiol. 2004;42:38313. DOIPubMedGoogle Scholar
  6. Odeh R, Kelkar S, Hujer AM, Bonomo RA, Schreckenberger PC, Quinn JP. Broad resistance due to plasmid-mediated AmpC β-lactamases in clinical isolates of Escherichia coli.Clin Infect Dis. 2002;35:1405. DOIPubMedGoogle Scholar
  7. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 15th ed. Vol. 25, no. 1. Approved standard M7–A6. Wayne (PA): The Institute; 2005.
  8. Poirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo JD, Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France.Antimicrob Agents Chemother. 2000;44:8917. DOIPubMedGoogle Scholar
  9. Lartigue MF, Fortineau N, Nordmann P. Spread of novel expanded-spectrum β-lactamases in Enterobacteriaceae in a university hospital in the Paris area, France.Clin Microbiol Infect. 2005;11:58891. DOIPubMedGoogle Scholar
  10. Lartigue MF, Poirel L, Nordmann P. Diversity of genetic environment of blaCTX-M genes.FEMS Microbiol Lett. 2004;234:2017. DOIPubMedGoogle Scholar
  11. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1989.
  12. Martinez-Martinez L, Conejo MC, Pascual A, Hernandez-Alles S, Ballesta S, Ramirez De Arellano-Ramos E, Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal β-lactamase and showing altered porin profiles.Antimicrob Agents Chemother. 2000;44:25346. DOIPubMedGoogle Scholar
  13. Jacoby GA, Sutton L. β-lactamases and β-lactam resistance in Escherichia coli.Antimicrob Agents Chemother. 1985;28:7035.PubMedGoogle Scholar
  14. Livermore DM, Oakton KJ, Carter MW, Warner M. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases.Antimicrob Agents Chemother. 2001;45:28317. DOIPubMedGoogle Scholar
  15. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community.J Antimicrob Chemother. 2005;56:529. DOIPubMedGoogle Scholar

Main Article

Page created: June 29, 2010
Page updated: June 29, 2010
Page reviewed: June 29, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external